GW Pharmaceuticals (GW Pharmaceuticals) Float Percentage Of Total Shares Outstanding : 84.60% (As of May. 05, 2024)

View and export this data going back to . Start your Free Trial

What is GW Pharmaceuticals Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, GW Pharmaceuticals's float shares is 320.24 Mil. GW Pharmaceuticals's total shares outstanding is 378.54 Mil. GW Pharmaceuticals's float percentage of total shares outstanding is 84.60%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, GW Pharmaceuticals's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, GW Pharmaceuticals's Institutional Ownership is 0.00%.

GW Pharmaceuticals Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

GW Pharmaceuticals's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	320.24	/	378.54
	=	84.60%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GW Pharmaceuticals (GW Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GW Pharmaceuticals PLC (OTCPK:GWPRF) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

Sovereign House, Chivers Way, Vision Park, Histon, Cambridge, GBR, CB24 9BZ

Website

http://www.gwpharm.com

GW Pharmaceuticals PLC is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The company's lead product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol used for the treatment of a number of rare childhood-onset epilepsy disorders. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. Geographically its presence can be seen across the region of UK, Europe, US, Canada, and others.